The link between obesity and pancreatic cancer just became clearer—and more actionable. This discovery challenges the long-held assumption that insulin drives obesity-related pancreatic tumors, revealing instead that a different hormone may be the true culprit behind one of medicine's deadliest cancers.
Mouse studies demonstrate that beta cells in the pancreas secrete cholecystokinin (CCK), a peptide hormone that directly promotes pancreatic adenocarcinoma development in obese conditions. Researchers found CCK expression, not insulin levels, strongly correlates with tumor formation. Through single-cell RNA sequencing and lineage tracing, they discovered obesity triggers expansion of immature beta cells that adapt to produce CCK via stress-activated JNK/cJun signaling pathways. This CCK then alters nearby exocrine cells, creating conditions favorable for tumor initiation near pancreatic islets.
This finding reframes our understanding of obesity-cancer mechanisms and opens promising therapeutic avenues. Pancreatic adenocarcinoma remains among the most lethal cancers, with five-year survival rates below 10 percent. Current treatments largely ignore the endocrine-exocrine communication networks this research illuminates. The identification of CCK as a key driver suggests targeting this hormone or its signaling pathway could prevent obesity-associated pancreatic cancer development. However, translating these mouse findings to humans requires validation studies, particularly since CCK plays important roles in digestion and satiety. The research also raises questions about whether CCK contributes to pancreatic cancer in non-obese individuals, potentially expanding the therapeutic relevance beyond obesity-related cases.